BlackRock’s Clinuvel Pharmaceuticals CUVL Stock Holding History

BlackRock’s Portfolio CUVL Stock Details CUVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.1K	Buy	+1,689	New	+$11K	﹤0.01%	5553

Other funds holding CUVL

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Shade Tree Advisors Saratoga Springs, New York $187M AUM 53.88% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

BlackRock's CUVL Position: Q3 2026 in Review

BlackRock opened a new position in Clinuvel Pharmaceuticals (CUVL) in Q3 2026: 1,689 shares worth $10.1K. The stake represents ﹤0.01% of the portfolio and ranks #5553 among its holdings.

6 funds tracked by Wall St. Rank hold CUVL as of Q3 2026.

BlackRock held 1,689 shares of Clinuvel Pharmaceuticals worth $10.1K as of Q3 2026.
Clinuvel Pharmaceuticals was a new BlackRock position in Q3 2026.
Clinuvel Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #5553 holding.
6 funds tracked by Wall St. Rank held Clinuvel Pharmaceuticals as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.